Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Therapeutic developments in amyotrophic lateral sclerosis.

E C Lai1

  • 1Baylor College of Medicine, Houston Veterans Affairs Medical Center, 6550 Fannin, Suite 1801, Houston, Texas 77030, USA. elai@bcm.tmc.edu

Expert Opinion on Investigational Drugs
|July 5, 2005
PubMed
Summary

Currently, no cure exists for amyotrophic lateral sclerosis (ALS). Riluzole and insulin-like growth factor-I (IGF-1) show promise in slowing disease progression and improving survival for ALS patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The relation of falls to fatigue, depression and daytime sleepiness in Parkinson's disease.

European neurology·2012
Same author

Effects of levodopa on forward and backward gait patterns in persons with Parkinson's disease.

NeuroRehabilitation·2011
Same author

An investigation of two interventions for micrographia in individuals with Parkinson's disease.

Clinical rehabilitation·2010
Same author

An evaluation of self-administration of auditory cueing to improve gait in people with Parkinson's disease.

Clinical rehabilitation·2009
Same author

Alleviation of drenching sweats following subthalamic deep brain stimulation in a patient with Parkinson's disease--a case report.

Journal of the neurological sciences·2009
Same author

Short and long-term motor and cognitive outcome of staged bilateral pallidotomy: a retrospective analysis.

Acta neurochirurgica·2007

Area of Science:

  • Neuroscience
  • Neurology
  • Pharmacology

Background:

  • Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by motoneurone degeneration.
  • Current treatments for ALS are largely ineffective, with a uniformly poor prognosis.
  • Therapeutic development is hindered by unknown etiology and patient variability.

Purpose of the Study:

  • To review current therapeutic strategies for amyotrophic lateral sclerosis (ALS).
  • To discuss emerging drug candidates and novel therapeutic approaches.
  • To highlight the importance of understanding ALS pathogenesis for future treatment development.

Main Methods:

  • Literature review of clinical studies and ongoing trials for ALS treatments.
  • Analysis of recent findings on riluzole and recombinant human insulin-like growth factor-I (IGF-1).

Related Experiment Videos

  • Discussion of potential therapeutic targets based on advancing theories of ALS pathogenesis.

    • Main Results:

    • Riluzole and IGF-1 have demonstrated benefits in improving survival or slowing disease progression in ALS patients.
    • Gabapentin and neurotrophic factors are under investigation in clinical trials.
    • Advances in understanding pathogenesis (genetics, excitotoxicity, oxidative stress) are guiding new therapies.

    Conclusions:

    • Future ALS therapies may include glutamate antagonists, neurotrophic factor enhancers, and antioxidants.
    • Combination therapy approaches should be considered for enhanced efficacy.
    • Further research into ALS pathogenesis is crucial for developing effective treatments.